Generic Medicine Info
Indications and Dosage
Adult: 240-480 mg daily. Severe depression: Up to 720 mg daily.
Elderly: Initially, 240 mg daily. Max: 480 mg daily.
Recent MI, arrhythmias, severe liver disease, manic phase.
Special Precautions
CV disease, history of epilepsy, hepatic impairment, hyperthyroidism, pheochromocytoma, history of mania, psychoses, urinary retention, close-angle glaucoma, concurrent electroconvulsive therapy, diabetes. Pregnancy and lactation, elderly, childn. Porphyria. Avoid abrupt withdrawal. May impair ability to drive.
Symptoms: lethargy, drowsiness, nausea, vomiting, and epigastric pain, GI bleeding. Hypertension, acute renal failure, respiratory depression, anaphylactoid reactions and coma may occur rarely. Management: treatment in symptomatic and supportive. There are no specific antidotes. Emesis and/or activated charcoal and/or osmotic cathartic may be reduce drug absorption if present within 4 hr of ingestion. Forced diuresis, alkalinization of urine, haemodialysis, or haemoperfusion unlikely to be useful.
Drug Interactions
Effects may be enhanced by concomitant use of cimetidine, diltiazem, disulfiram, methylphenidate, ritonavir and verapamil and reduced when used with carbamazepine, rifampicin and oestrogens. Side-effects may be increased by adrenaline, amiodarone, general anaesthetics, SSRIs, anithistamines, antimuscarinics, antipsychotics, anxiolytics and hypnotics, disopyramide, diuretics, flecainide, MAOIs, moclobemide, moxifloxacin, nefopam, nicorandil, noradrenaline, pimozide, procainamide, propafenone, quinidine, selegiline, sibutramine, sotalol, terfenadine, thioridazine and tramadol. Effects of adrenergic neuron blocker, clonidine, barbiturates, nitrates, and primidone are reduced while effects of baclofen, opioid analgesics and thyroid hormones are enhanced.
Potentially Fatal: Concomitant use with brimonidine, entacapone, artemether with lumefantrine should be avoided.
Lab Interference
Abnormal liver function test.
Mechanism of Action: Dibenzepin is a tricyclic antidepressant.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Dibenzepin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in